Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06941480 · ClinicalTrials.gov registry record · Phase 1
A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Not yet
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT06941480: Clinical Trial Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06941480 is a Phase 1 study that has not yet begun recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06941480, a Phase 1 study, has not yet begun recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to find out whether 177Lu-DTPA-SC16.56 is a safe treatment for people with small-cell lung cancer or neuroendocrine prostate cancer
Interventions
- DIAGNOSTIC_TEST PET/CT
- BIOLOGICAL 177Lu-DTPA-SC16.56
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-06 |
| Est. Completion | 2030-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06941480
The ClinicalTrials.gov registry entry for NCT06941480 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PET/CT is the first listed.
NCT06941480 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06941480 about?
NCT06941480 is a clinical study titled "A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate". The purpose of this study is to find out whether 177Lu-DTPA-SC16.56 is a safe treatment for people with small-cell lung cancer or neuroendocrine prostate cancer
What is the current status of trial NCT06941480?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-06. Estimated completion is 2030-05.
What interventions are being tested in trial NCT06941480?
The interventions under investigation include: PET/CT (DIAGNOSTIC_TEST), 177Lu-DTPA-SC16.56 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06941480?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.